Molecular profiling from Caris Diagnostics was utilized to determine the course of treatment for each patient with different types of cancers. For breast cancer the period of progression-free survival increased 44 percent, so overall the question of whether or not personalized medicine works seems to have been answered in this study. BD
TGen, Scottsdale Healthcare and Caris Dx clinical trial shows molecular profiling can result in specific treatments for individual patients that significantly limit the growth and spread of tumors
PHOENIX, Ariz. - April 19, 2009 - Cancer patients can survive longer under treatments based on their individual genetic profiles, according to a nationwide study released jointly today by Phoenix-area healthcare organizations.
The study shows that molecular profiling of patients can identify specific treatments for individuals, helping keep their cancer in check for significantly longer periods, and in some cases even shrinking tumors. The study included 66 patients at nine centers across the United States, including Scottsdale Healthcare. Dr. Von Hoff also is the Chief Scientific Officer of TGen Clinical Research Services (TCRS) at Scottsdale Healthcare, a partnership between TGen and Scottsdale Healthcare that is administered by the Scottsdale Clinical Research Institute (SCRI) at Scottsdale Healthcare.